Among 1163 patients receiving PD-1 inhibitors, 1.8% satisfied the criteria for ICI-induced DM, whereas none of the 281 patients receiving the CTLA-4 inhibitor ipilimumab developed DM (89). Here, CTLA4 is linked to diabetes mellitus.